{
  "docId": "019dd923-622c-750b-8b97-5cb48bf2a635",
  "docSlug": "b8afd3741673",
  "documentTitle": "Chinook Therapeutics Inc (KDNY)",
  "authorId": "51_Muddy_Waters",
  "authorName": "Carson C. Block",
  "documentKindSlug": "research-note",
  "documentKindLabel": "Research note",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2023-05-16 00:00:00",
  "orientation": "portrait",
  "aspectRatio": 0.77272725,
  "pageNumber": 29,
  "pageCount": 36,
  "prevPage": 28,
  "nextPage": 30,
  "slideType": "expose_contradiction",
  "function": "expose_contradiction",
  "density": "balanced",
  "nDataPoints": 2,
  "notes": "The slide uses a 'villain critique' approach to undermine the credibility of the company's clinical trial reporting.",
  "elementsJson": [
    "paragraph",
    "screenshot",
    "footnote"
  ],
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b97-5cb48bf2a635/29",
  "deckHref": "/decks/019dd923-622c-750b-8b97-5cb48bf2a635",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b97-5cb48bf2a635.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b97-5cb48bf2a635#slide-29",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "So Chinook’s claims—that (1) atrasentan has been studied in >5,100 patients and (2) that it showed an acceptable safety profile—are both distortions.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-25b7-709e-b8d1-f2a33bb005d8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.552,
        "x": 0.224,
        "y": 0.285
      },
      "kind": "other",
      "text": "Atrasentan* Blockade of the ETA receptor... Atrasentan has demonstrated clinically significant and sustained proteinuria reduction with an acceptable safety profile in over 5,100 patients with DKD",
      "attrs": null,
      "subkind": "unclassified",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "12f8f165-e69a-4bff-b8d9-2071f4d726ec",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.125,
        "w": 0.764,
        "x": 0.118,
        "y": 0.607
      },
      "kind": "paragraph",
      "text": "Chinook has initiated two clinical trials into the efficacy of atrasentan for kidney disease... A close examination of the results Chinook has already disclosed from these trials will demonstrate that they are not, indeed cannot be, the basis for Chinook's apparent value.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8b27881a-a61a-4fca-9534-0bf44644cd5a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.125,
        "w": 0.764,
        "x": 0.118,
        "y": 0.163
      },
      "kind": "paragraph",
      "text": "But SONAR, which is the largest study of atrasentan advanced only 3,666 patients out of the original ~5,100 to the double-blind treatment period... So Chinook's claims—that (1) atrasentan has been studied in >5,100 patients and (2) that it showed an acceptable safety profile—are both distortions.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e41303d7-ec39-4ba8-91fa-ec1a0dfa0301",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "[n]o SAEs related to the study drug [atrasentan] to date. — Chinook Therapeutics",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-25b7-709e-b8d1-f71805c95a71",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.125,
        "w": 0.764,
        "x": 0.118,
        "y": 0.807
      },
      "kind": "source-note",
      "text": "146 See Appendix. 147 Atrasentan for the Treatment of IgA Nephropathy - Interim Results - AFFINITY Study, May 2022, p.8... 148 https://clinicaltrials.gov/ct2/show/NCT04573478... 149 http://repo.dma.dp.ua/6035/1/SONAR.pdf",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9ad8f704-d8fc-4c72-972e-677499a617ac",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "fraud-exposure",
      "slug": null,
      "matchId": "8126f890-2c22-490e-a882-dfaf735ad0fb",
      "evidence": "The slide explicitly labels company claims as 'distortions' and 'misleading and deceptive style of communication'.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 33,
      "from": 28,
      "beatId": "640ed796-f0a7-4d27-b017-41863f0ffedf",
      "arcName": "Overcoming the Monster",
      "arcSlug": "overcoming-monster",
      "beatName": "The Victory",
      "beatSlug": "overcoming-monster-the-victory",
      "evidence": "The report presents the 'victory' of Muddy Waters Research in uncovering the truth",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 33,
      "from": 28,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "6980f318-c257-42fa-96be-f6e3de335b06",
      "evidence": "The report implies that investors and analysts should be cautious",
      "position": 1,
      "objective": "To highlight the consequences of not addressing the issues with the trial results",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}